

Capivasertib, pan-AKT inhibitor

Catalog	Unit
TBI4383-5MG	5 mg
TBI4383-25MG	25 mg

Product Details

Formal Name: 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

Alternate Names: AZD5363

Molecular Formula: C₂₁H₂₅ClN₆O₂

Formula Weight: 428.9

CAS Number: 1143532-39-1


Purity: >98%

Formulation: Powder

Solubility: Soluble in DMSO (up to at least 50 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.



Applications

pan-AKT inhibitor

Functions

Potent ATP-competitive pan-Akt inhibitor (IC₅₀s: Akt1 = 3 nM, Akt2 = 8 nM, Akt3 = 8 nM). It reduced tumor vascular density, decreased influx of myeloid cells, and reduced tumor regrowth in hepatocarcinoma models in conjunction with radiotherapy. Capivasertib significantly reduced cancer migration and invasion in a colorectal cancer model. It enhanced CAR-T cell activity in B cell lymphoma models. FDA approved for the treatment of HR+/HER2-negative breast cancer.

Application Procedures

First dissolved in DMSO (up to at least 50 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.